Peptide Vaccines for Hypertension and Diabetes Mellitus
Vaccines are commonly used as a preventive medicine for infectious diseases worldwide; however, the trial for an amyloid beta vaccine against Alzheimer’s disease will open a new concept in vaccination. In case of therapeutic vaccines for cancer, their targets are usually specific antigens in cancer...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2076-393X/2/4/832 |
| _version_ | 1811300834730835968 |
|---|---|
| author | Hironori Nakagami Hiroshi Koriyama Ryuichi Morishita |
| author_facet | Hironori Nakagami Hiroshi Koriyama Ryuichi Morishita |
| author_sort | Hironori Nakagami |
| collection | DOAJ |
| description | Vaccines are commonly used as a preventive medicine for infectious diseases worldwide; however, the trial for an amyloid beta vaccine against Alzheimer’s disease will open a new concept in vaccination. In case of therapeutic vaccines for cancer, their targets are usually specific antigens in cancer cells, allowing activated cytotoxic T cells (CTLs) to attach and remove the antigen-presenting cancer cells. In our therapeutic vaccines against hypertension, the target is angiotensin II (Ang II) and induced anti-Ang II antibodies could efficiently ameliorate high blood pressure. Similarly, we developed the therapeutic vaccine against DPP4 for diabetes mellitus. However, because Ang II or DPP4 is an endogenous hormone, we must avoid autoimmune disease induced by these vaccines. Therefore, our system was used to design a therapeutic vaccine that elicits anti-Ang II or DPP4 antibodies without CTL activation against Ang II or DPP4. In this review, we will describe our concept of therapeutic vaccines for hypertension and diabetes mellitus. |
| first_indexed | 2024-04-13T06:58:05Z |
| format | Article |
| id | doaj.art-b6bf5d9642cf4d6f9eddfc3a537c6f90 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-04-13T06:58:05Z |
| publishDate | 2014-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-b6bf5d9642cf4d6f9eddfc3a537c6f902022-12-22T02:57:12ZengMDPI AGVaccines2076-393X2014-11-012483284010.3390/vaccines2040832vaccines2040832Peptide Vaccines for Hypertension and Diabetes MellitusHironori Nakagami0Hiroshi Koriyama1Ryuichi Morishita2Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, Chiba University, Fukui University, 2-1 Yamada-oka, Suita, Osaka 565-0871, JapanDivision of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, Chiba University, Fukui University, 2-1 Yamada-oka, Suita, Osaka 565-0871, JapanDepartment of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, JapanVaccines are commonly used as a preventive medicine for infectious diseases worldwide; however, the trial for an amyloid beta vaccine against Alzheimer’s disease will open a new concept in vaccination. In case of therapeutic vaccines for cancer, their targets are usually specific antigens in cancer cells, allowing activated cytotoxic T cells (CTLs) to attach and remove the antigen-presenting cancer cells. In our therapeutic vaccines against hypertension, the target is angiotensin II (Ang II) and induced anti-Ang II antibodies could efficiently ameliorate high blood pressure. Similarly, we developed the therapeutic vaccine against DPP4 for diabetes mellitus. However, because Ang II or DPP4 is an endogenous hormone, we must avoid autoimmune disease induced by these vaccines. Therefore, our system was used to design a therapeutic vaccine that elicits anti-Ang II or DPP4 antibodies without CTL activation against Ang II or DPP4. In this review, we will describe our concept of therapeutic vaccines for hypertension and diabetes mellitus.http://www.mdpi.com/2076-393X/2/4/832vaccineangiotensin IIDPP4 |
| spellingShingle | Hironori Nakagami Hiroshi Koriyama Ryuichi Morishita Peptide Vaccines for Hypertension and Diabetes Mellitus Vaccines vaccine angiotensin II DPP4 |
| title | Peptide Vaccines for Hypertension and Diabetes Mellitus |
| title_full | Peptide Vaccines for Hypertension and Diabetes Mellitus |
| title_fullStr | Peptide Vaccines for Hypertension and Diabetes Mellitus |
| title_full_unstemmed | Peptide Vaccines for Hypertension and Diabetes Mellitus |
| title_short | Peptide Vaccines for Hypertension and Diabetes Mellitus |
| title_sort | peptide vaccines for hypertension and diabetes mellitus |
| topic | vaccine angiotensin II DPP4 |
| url | http://www.mdpi.com/2076-393X/2/4/832 |
| work_keys_str_mv | AT hironorinakagami peptidevaccinesforhypertensionanddiabetesmellitus AT hiroshikoriyama peptidevaccinesforhypertensionanddiabetesmellitus AT ryuichimorishita peptidevaccinesforhypertensionanddiabetesmellitus |